Medtronic/$MDT
1D1W1MYTD1Y5YMAX
Capital at risk
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
- Ticker
- $MDT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 95,000
- Headquarters
- Galway, Ireland
- Website
- www.medtronic.com
Medtronic Metrics
BasicAdvanced
$118B
22.69
$4.06
0.57
$2.85
3.13%
Price and volume
Market cap
$118B
Beta
0.57
52-week high
$106.33
52-week low
$73.31
Average daily volume
8.1M
Dividend rate
$2.85
Financial strength
Current ratio
2.067
Quick ratio
1.286
Long term debt to equity
0.504
Total debt to equity
0.582
Dividend payout ratio (TTM)
69.78%
Interest coverage (TTM)
10.46%
Profitability
EBITDA (TTM)
10,404
Gross margin (TTM)
65.27%
Net profit margin (TTM)
13.93%
Operating margin (TTM)
20.10%
Effective tax rate (TTM)
20.19%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
5.12%
Return on equity (TTM)
10.65%
Valuation
Price to earnings (TTM)
22.695
Price to revenue (TTM)
3.144
Price to book
2.35
Price to tangible book (TTM)
-36.07
Price to free cash flow (TTM)
19.252
Free cash flow yield (TTM)
5.19%
Free cash flow per share (TTM)
4.786
Dividend yield (TTM)
3.09%
Forward dividend yield
3.13%
Growth
Revenue change (TTM)
9.77%
Earnings per share change (TTM)
12.12%
3-year revenue growth (CAGR)
5.96%
10-year revenue growth (CAGR)
2.71%
3-year earnings per share growth (CAGR)
14.42%
10-year earnings per share growth (CAGR)
4.68%
3-year dividend per share growth (CAGR)
1.44%
10-year dividend per share growth (CAGR)
6.14%
What the Analysts think about Medtronic
Analyst ratings (Buy, Hold, Sell) for Medtronic stock.
Analyst projections of the future price of Medtronic stock.
Bulls say / Bears say
Medtronic beat Wall Street’s Q4 estimates with $9.8 billion in revenue (up 9.9 percent reported, 6.6 percent organic) and non-GAAP EPS of $1.55, driven by robust demand for pulsed field ablation and transcatheter heart valve therapies (Reuters)
In March, the FDA approved Medtronic’s OmniaSecure defibrillation lead—the world’s first lumenless lead cleared for left bundle branch area pacing—bolstering its electrophysiology portfolio (Reuters)
Medtronic agreed to acquire Scientia Vascular for $550 million to expand its neurovascular stroke-care offerings, with the deal expected to close in the first half of fiscal 2027 (Reuters)
A federal jury in August awarded $88 million in the first hernia mesh trial against Medtronic, highlighting the potential for substantial liability across thousands of pending cases (Reuters)
Medtronic’s Q4 non-GAAP operating margin declined 230 basis points to 25.5 percent, pressured by inflation, MiniMed separation costs, and increased tariffs (PRNewswire)
Tariff headwinds are expected to hit Medtronic by about $300 million in fiscal 2027—up from $185 million in FY 2026—potentially dampening profitability and cash flow (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Medtronic Financial Performance
Revenues and expenses
Medtronic Earnings Performance
Company profitability
Upcoming events
Medtronic News
AllArticlesVideos
Funds containing Medtronic
AllEURGBPUSD
Fund name | Fund size | $MDT weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 1.95% |
SPDR S&P US Dividend Aristocrats€SPYD | €3.3B | 1.85% |
SPDR S&P US Dividend Aristocrats£USDV | £2.8B | 1.85% |
iShares AI Adopters and Applications€AIAA | €169M | 1.75% |
iShares AI Adopters and Applications£AIAA | £145M | 1.75% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.